INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 169 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q2 2017. The put-call ratio across all filers is 0.59 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2020 | $1,909,000 | +181.6% | 46,055 | +722.4% | 0.05% | +500.0% |
| Q2 2017 | $678,000 | -32.7% | 5,600 | -8.6% | 0.01% | -38.5% |
| Q3 2016 | $1,008,000 | -15.9% | 6,124 | +44.1% | 0.01% | -61.8% |
| Q1 2015 | $1,198,000 | +327.9% | 4,249 | +259.2% | 0.03% | +161.5% |
| Q3 2014 | $280,000 | -91.7% | 1,183 | -91.7% | 0.01% | -90.6% |
| Q2 2014 | $3,362,000 | +918.8% | 14,204 | +1320.4% | 0.14% | +557.1% |
| Q1 2014 | $330,000 | – | 1,000 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Sarissa Capital Management LP | 635,300 | $53,308,000 | 10.69% |
| Senvest Management, LLC | 976,127 | $81,907,000 | 5.65% |
| Melqart Asset Management (UK) Ltd | 390,600 | $32,775,000 | 2.80% |
| Asymmetry Capital Management, L.P. | 25,918 | $2,175,000 | 2.14% |
| Elk Creek Partners, LLC | 386,397 | $32,423,000 | 1.78% |
| BB BIOTECH AG | 545,719 | $45,791,000 | 1.32% |
| ALTRINSIC GLOBAL ADVISORS LLC | 383,166 | $32,151,000 | 1.27% |
| DLD Asset Management, LP | 129,000 | $10,824,000 | 0.82% |
| Opus Point Partners Management, LLC | 3,998 | $335,000 | 0.73% |
| Virtus ETF Advisers LLC | 8,970 | $753,000 | 0.67% |